Matching articles for "PDE5 inhibitor"
Issue 1509 · December 5, 2016
Sublingual Nitroglycerin Powder (GoNitro)

The FDA has approved a sublingual powder formulation of nitroglycerin ( GoNitro – Espero) for prevention or acute relief of an attack of angina pectoris. It is the first powder formulation of nitroglycerin…

Med Lett Drugs Ther. 2016 Dec 5; 58(1509):156-7
The FDA has approved a sublingual powder formulation of nitroglycerin ( GoNitro – Espero) for prevention or acute relief of an attack of angina pectoris. It is the first powder formulation of nitroglycerin to become available in the US. Most patients with angina use sublingual nitroglycerin tablets ( Nitrostat , and generics). Translingual spray formulations of nitroglycerin ( NitroMist , Nitrolingual Pumpspray , and generics) are also available.
Issue 1488 · February 15, 2016
Selexipag (Uptravi) for Pulmonary Arterial Hypertension

The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral…

Med Lett Drugs Ther. 2016 Feb 15; 58(1488):21-3
The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral prostacyclin analog, was approved earlier for this indication.
Issue 1442 · May 12, 2014
Avanafil (Stendra) - Another PDE5 Inhibitor for Erectile Dysfunction

The FDA has approved avanafil ( Stendra – Vivus), an oral phosphodiesterase type-5 (PDE5) inhibitor, for treatment of erectile dysfunction. It is the fifth PDE5 inhibitor to be approved for this indication.…

Med Lett Drugs Ther. 2014 May 12; 56(1442):37-8
The FDA has approved avanafil ( Stendra – Vivus), an oral phosphodiesterase type-5 (PDE5) inhibitor, for treatment of erectile dysfunction. It is the fifth PDE5 inhibitor to be approved for this indication. Advertisements on Stendra ’s website imply that it has a faster onset of action than other PDE5 inhibitors.
Issue 1437 · March 3, 2014 Free
In Brief: Testosterone and Cardiovascular Risk

Prompted by the recent publication of 2 retrospective studies, the FDA has announced that it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. 1 The…

Med Lett Drugs Ther. 2014 Mar 3; 56(1437):17
Prompted by the recent publication of 2 retrospective studies, the FDA has announced that it is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products. 1 The first study examined the records of 8709 men with low testosterone levels (<300 ng/dL) who underwent coronary angiography between 2005 and 2011; 1223 of these men started testosterone therapy after a median of 531 days following coronary angiography. Three years after coronary angiography, the Kaplan-Meier estimated cumulative percentages of men who died or had a myocardial infarction (MI) or ischemic stroke were 26% of those treated with testosterone and 20% of those who were not treated with the hormone, a hazard ratio of 1.29 (95% CI 1.04-1.58; P=0.02). 2 The second study compared the rate of nonfatal MI during the 90 days after filling a prescription with the rate in the prior year in 56,000 men given a prescription for testosterone and in 167,000 given a phosphodiesterase type 5 inhibitor (sildenafil [Viagra] or tadalafil [Cialis] ). In the testosterone group as a whole, the post/pre-prescription rate ratio was 1.36, but in men ≥65 years old it was 2.19 and in younger men with a history of heart disease it was 2.90. In men who received a prescription for sildenafil or tadalafil, the rate ratio was 1.08 for all ages, 1.15 for those ≥65 years old, and 1.40 for younger men with a history of heart disease. 3 A recent meta-analysis of randomized, placebo-controlled trials of testosterone therapy also found an increased risk of cardiovascular-related events in men treated with the hormone (odds ratio [OR] 1.54; 95% CI 1.09-2.18); an analysis by funding source found that the risk was greater in trials not funded by the pharmaceutical industry (OR 2.06 vs. 0.89). 4 1. FDA Drug Safety Communication January 31, 2014: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Available at www.fda.gov. Accessed February 24, 2014. 2. R Vigen et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310:1829. 3. WD Finkle et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9:e85805. 4. L Xu et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11:108. Download complete U.S. English article
Issue 1429 · November 11, 2013
A Prostatic Urethral Lift for Benign Prostatic Hyperplasia

The FDA has approved the use of a permanent prostatic urethral lift implant ( UroLift – NeoTract) to relieve low or blocked urine flow in men ≥50 years old with benign prostatic hyperplasia (BPH).

Med Lett Drugs Ther. 2013 Nov 11; 55(1429):91
The FDA has approved the use of a permanent prostatic urethral lift implant ( UroLift – NeoTract) to relieve low or blocked urine flow in men ≥50 years old with benign prostatic hyperplasia (BPH).
Issue 1383 · February 6, 2012
PDE5 Inhibitors for Erectile Dysfunction

Sildenafil (Viagra) , tadalafil (Cialis) and vardenafil (Levitra, Staxyn) have become the standard treatment for erectile dysfunction. Head-to-head comparisons of these agents are still lacking, but some…

Med Lett Drugs Ther. 2012 Feb 6; 54(1383):10-1
Sildenafil (Viagra) , tadalafil (Cialis) and vardenafil (Levitra, Staxyn) have become the standard treatment for erectile dysfunction. Head-to-head comparisons of these agents are still lacking, but some differences between them and new recommendations for their dosing (see Table 2) are worth noting.
Issue 1324 · November 2, 2009
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

The FDA has approved use of tadalafil ( Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).

Med Lett Drugs Ther. 2009 Nov 2; 51(1324):87-8
The FDA has approved use of tadalafil ( Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).
Issue 1283 · April 7, 2008
Tadalafil (Cialis) Once a Day for Erectile Dysfunction

The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):27-8
The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil (Levitra) , the other PDE5 inhibitors marketed for erectile dysfunction in the US, in having a much longer duration of action.